acu193 questionI think I opined last year that the acu193 story had a hole in it for Promis investors: it entirely ignores the role of misfolding. This seems relevant now that their stock price is down huge, but I'm not sure there's actually a connection as their P1 schedule has been pushed back.
So the question is, am I mssing something with Acumen or is their hypothesis simply that all ABOs are bad, so while some mers are worse than others it's safe tp target them all? I feel like I must have it wrong because that logic doesn't explain AD progression, leaving it to cascade effects with presumably other individually variable triggers.
With Promis and Acumen now on very similar time lines through P1 the market will be looking for differentiation, but neither company will whizz on the other's parade so what will be the strategy? .